Science Daily: Pharmacology News

JULY 12, 2023

Researchers have demonstrated that a transplant surgical procedure (called 'needle trauma') triggers a profound immune response and causes the death of most grafted dopamine neurons. These findings suggest a path for the 'realistic' use of cell therapy to treat neurodegenerative disorders.

Therapies 69

Therapies Immune Response Disease Research 69

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants have saved patients’ lives time and time again, which led us to launch our own Stem Cell Transplant and Cellular Therapy Program. Stem cell transplants primarily help the immune response through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.”

Therapies 64

Therapies Treatment FDA Approval Vaccine 64

Drug Target Review

JANUARY 23, 2024

Cell-based therapies, such as tumour-infiltrating lymphocyte (TIL) therapy, have also drawn significant attention following promising results in a melanoma trial. Such approaches apply artificial intelligence (AI) and machine learning (ML) to predict mutations most likely to be good targets for the immune system.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

Drug Discovery World

OCTOBER 13, 2023

The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses. Another important application of EVEscape would be to evaluate vaccines and therapies against current and future viral variants.

Vaccine 264

Vaccine Virus Medical Schools Immune Response 264

Drug Discovery World

JANUARY 31, 2023

Grey Wolf Therapeutics has closed an oversubscribed $49 million Series B financing co-led by Pfizer Ventures and Earlybird Venture Capital, with investment from Oxford Science Enterprises, British Patient Capital, Canaan and Andera Partners. Proceeds will support the continued development of the company’s first-of-its-kind immuno-oncology approaches (..)

Immune Response 130

Immune Response Clinical Trials Science Therapies 130

Drug Discovery World

APRIL 11, 2024

Together with my colleagues, I am tackling what is one of the most pressing problems in biotech, the discovery of targets to serve as the basis for new therapies for cancer and infectious diseases. By understanding what triggers the adaptive immune response in “elite responders” we have identified new targets and therapeutic antibodies.

Research 147

Research Immune Response Disease Laboratories 147

Drug Discovery World

JULY 5, 2023

It’s a brilliantly exciting time where we’re beginning to harvest the fruits of decades’ worth of breakthrough research undertaken by the world’s brightest scientists, and we’re seeing those advances in basic science translated to the clinic, where they’re making a difference in patients’ lives.

Research 246

Research Immune Response Pharmaceutical Companies Treatment 246

The Pharma Data

APRIL 22, 2023

These “acute inflammatory lesions” then attract other myeloid cells, as well as self-reactive T and B cells that belong to the immune system’s second arm, known as the “adaptive immune system” and directly attack the myelin covering. “Current MS therapies do not specifically target myeloid cells.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

Drug Discovery World

MAY 6, 2024

Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany. billion ($7.9

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

Drug Discovery World

JANUARY 22, 2024

It states: ” An integrated appreciation of the physiological consequences of DUB modulation in relevant cancer models will eventually lead to the identification of patient populations that will most likely benefit from DUB-targeted therapies” 1.

Immune Response 147

Immune Response Vaccine Engineering Virus 147

Drug Target Review

MAY 14, 2024

The combination of P1 with antiPD1 more efficiently activated innate and adaptive immune responses than either P1 or antiPD1 alone by re-energising T cell effector functions, thus providing the remarkable reduction of tumour growth in solid tumours and extended survival period.

Engineering 59

Engineering Immune Response FDA Approval DNA 59

Olympian Clinical Research

MAY 6, 2024

As medical understanding grew, so did the sophistication of the therapies. These targeted therapies revolutionized treatment, offering relief to severe cases by specifically addressing the underlying immune responses causing the disease.

Treatment 52

Treatment Small Molecule Immune Response Clinical Research 52

Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 105

Immune Response Laboratories DNA Virus 105

The Pharma Data

APRIL 15, 2022

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

Drug Target Review

OCTOBER 19, 2023

Their research centres around a remarkable immune protein called IL-31, which not only induces itching but also plays a crucial role in regulating inflammation. In the absence of IL-31, these nerve cells failed to control the immune system, leading to unchecked inflammation.

Immune Response 104

Immune Response Regulations Treatment Therapies 104

Drug Discovery World

FEBRUARY 28, 2024

Results from the trial, published in Nature Communications by researchers from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, found that MOv18 IgE was well-tolerated in the majority of patients and was able to shrink the tumour of a patient with ovarian cancer who had not responded to conventional therapy.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Drug Target Review

OCTOBER 26, 2023

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications.

Engineering 105

Engineering Virus Therapies Immune Response 105

Drug Target Review

OCTOBER 16, 2023

This is particularly pertinent in immune-based cell therapies like CAR-T, where animals do not mimic the human immune response. The full potential of PDOs would be to shorten the time and costs associated with medicine creation, and then use PDO therapies to treat patients effectively.

Disease 122

Disease Immune Response Cell Biology Engineering 122

Drug Target Review

NOVEMBER 6, 2023

2 It is this complexity that necessitates powerful, targeted combination therapies. 4, 5 More recently, new combination regimens have emerged that incorporate targeted therapies to treat a variety of blood cancers, including multiple myeloma (MM), chronic lymphocytic leukaemia (CLL) and acute myelogenous leukaemia (AML).

Small Molecule 111

Small Molecule Therapies Treatment Immune Response 111

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Drug Discovery World

JULY 29, 2022

muciniphila plays a key role in maintaining healthy immune processes, seeming to protect against diseases such as Type 2 diabetes and inflammatory bowel disease and make cancer cells more responsive to immune checkpoint therapies. muciniphila’s ability to manipulate the immune system and fight disease.

Research 130

Research Immune Response Medical Schools Disease 130

Drug Target Review

JANUARY 15, 2024

Researchers from the Nara Institute of Science and Technology (NAIST) have used the reverse-blastocyst complementation (rBC) method to understand the conditions required to form lungs in rat-mouse chimeric models. Pluripotent Stem Cell-Based Cell Therapy – Promise and Challenges. The Pathology of Chronic Obstructive Pulmonary Disease.

Immune Response 113

Immune Response Disease Science Therapies 113

PLOS: DNA Science

JANUARY 4, 2024

The end-of-year FDA approval of the first CRISPR-based therapy , for sickle cell disease, came a mere dozen years after Jennifer Doudna and Emmanuelle Charpentier introduced the technology. The microbes deploy them to dismantle the genetic material of infecting viruses, a little like an immune response.

FDA Approval 52

FDA Approval DNA Clinical Trials Therapies 52

The Pharma Data

SEPTEMBER 8, 2020

About AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

Drug Target Review

APRIL 3, 2024

Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences. Being an only child of non-academic parents, I learned to work and study independently early on.

Science 105

Science Clinical Development DNA Treatment 105

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Clinical Trials 130

Clinical Trials Research Science Clinical Research 130

DrugBank

MAY 6, 2024

Unlike conventional chemical-based medicines, biologics offer targeted therapies derived from living cells, which can result in more effective and personalized treatments. A Wave of Innovations The year 2024 has already proven to be significant for the field of biologics, witnessing a notable increase in FDA approvals.

FDA Approval 66

FDA Approval Therapies Treatment Clinical Trials 66

The Pharma Data

SEPTEMBER 8, 2020

LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. About AstraZeneca.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 10, 2020

Weiner, chairman of the scientific advisory board of Tiziana Life Sciences, commented: “We understand that this will be the first-ever study with ‘take-home’ capsules of any mAb for immunotherapies for human diseases. Phase1b/2 clinical study to be conducted in the United States and several European countries. and Europe.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

MAY 15, 2023

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera Gilead Sciences, Inc. Executive Vice President, Research, Gilead Sciences. About Gilead Sciences Gilead Sciences, Inc. The company was founded in 2021 by Stephen Kaldor, Ph.D., Qing Dong, Ph.D., and Gene Hung, M.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

Drug Discovery World

APRIL 15, 2023

As the theme, Advancing the Frontiers of Cancer Science and Medicine , suggests, a number of announcements, results and presentations will take place at what is widely considered to be a flagship event for the cancer research community. BDC-3042 is an agonistic antibody targeting Dectin-2, an immune-activating receptor expressed by TAMs.

Virus 130

Virus Clinical Trials Trials Therapies 130

DrugBank

MAY 15, 2024

This method was more about serendipity than science. 5 This period also saw the rise of biologics in the 1980s, which have played a crucial role in modern therapies, particularly for diseases like cancer. The Evolution of Drug Discovery: From Dark Rooms to Precision Targets In the past, drug discovery often felt like a lucky guess.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

Broad Institute

JULY 26, 2022

Researchers decipher how a gut bacterium influences immunity By Corie Lok July 26, 2022 Breadcrumb Home News Researchers decipher how a gut bacterium influences immunity Study finds a molecule made by the bacterium that helps moderate immune responses. Study after study had suggested that A. muciniphila ’s cell membrane.

Research 52

Research Immune Response Medical Schools Disease 52

The Pharma Data

NOVEMBER 17, 2020

Located in Oss, the Netherlands, Lead Pharma is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for patients suffering from autoimmune diseases (a subset of immune-mediated diseases) and cancer. . This includes therapies against the nuclear receptor ROR?t,

Small Molecule 52

Small Molecule Disease Immune Response Licensing 52

Drug Target Review

FEBRUARY 5, 2024

Dr Ashley Seifert, an associate professor in the Department of Biology at the UK College of Arts and Sciences, and his research group have pioneered the use of spiny mice and other animal models to understand how complex tissue can regenerate, bridging regenerative biology and medicine. The Innate Immune Response to Infection [Internet].

Laboratories 59

Laboratories Immune Response Regulations RNA 59

Broad Institute

JUNE 27, 2024

Science (2024) Related content New gene delivery vehicle shows promise for human brain gene therapy My Quest to Cure Prion Disease — Before It’s Too Late | Sonia Vallabh | TED Prion diseases lead to rapid neurodegeneration and death and are caused by misshapen versions of the prion protein in the brain.

Disease 142

Disease Therapies Engineering Clinical Trials 142